Discovery of narlaprevir (SCH 900518): A potent, second generation HCV NS3 serine protease inhibitor

ACS Medicinal Chemistry Letters

Volumn 1, Issue 2, 2010, Pages 64-69

  Arasappan, Ashok ^a   Bennett, Frank ^a   Bogen, Stephane L ^a   Venkatraman, Srikanth ^a   Blackman, Melissa ^a   Chen, Kevin X ^a   Hendrata, Siska ^a   Huang, Yuhua ^a   Huelgas, Regina M ^a   Nair, Latha ^a   Padilla, Angela I ^a   Pan, Weidong ^a   Pike, Russell ^a   Pinto, Patrick ^a   Ruan, Sumei ^a   Sannigrahi, Mousumi ^a   Velazquez, Francisco ^a   Vibulbhan, Bancha ^a   Wu, Wanli ^a   Yang, Weiying ^a   Saksena, Anil K ^a   Girijavallabhan, Viyyoor ^a   Shih, Neng Yang ^a   Kong, Jianshe ^a   Meng, Tao ^a   Jin, Yan ^a   Wong, Jesse ^a   McNamkra, Paul ^a   Prongay, Andrew ^a   Madison, Vincent ^a   Piwinski, John J ^a   Cheng, Kuo Chi ^a   Morrison, Richard ^a   Malcolm, Bruce ^a   Tong, Xiao ^a   Ralston, Robert ^a   Njoroge, F George ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

ketoamide; Hepatitis C virus NS3 serine protease inhibitor; narlaprevir; SCH 900518

Indexed keywords

NARLAPREVIR; SCH 900518; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PHYSICOCHEMICAL MODEL; PRIORITY JOURNAL; RAT; STRUCTURE ACTIVITY RELATION;

HEPATITIS C VIRUS;

EID: 77956533506     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml9000276     Document Type: Article

References (23)

1. Cohen, J. The scientific challenge of hepatitis C Science 1999, 285, 26-30
2. Lavanchy, D. The global burden of hepatitis C Liver Int. 2009, 29 (s1) 74-81
3. Dymock, B. W. Emerging therapies for hepatitis C infection Emerging Drugs 2001, 6 (1) 13-42
4. Feld, J. J.; Hoofnagle, J. H. Mechanism of action of interferon and ribavirin in treatment of hepatitis C Nature 2005, 436, 967-972
5. Meanwell, N. A.; Kadow, J. F.; Scola, P. M. Progress toward the discovery and development of specifically targeted inhibitors of hepatitis C virus Annu. Rep. Med. Chem. 2009, 44) 397-440
6. Kolykhalov, A. A.; Mihalik, K.; Feinstone, S. M.; Rice, C. M. Hepatitis C virus-encoded enzymatic activities and conserved RNA elements in the 3? nontranslated region are essential for virus replication in vivo J. Virol. 2000, 74, 2046-2051
7. Bartenschlager, R.; Lohmann, V. Replication of hepatitis C virus J. Gen. Virol. 2000, 81, 1631-1648
8. Chen, K. X.; Njoroge, F. G. A review of HCV protease inhibitors Curr. Opin. Invest. Drugs 2009, 10 (8) 821-837
9. Lamarre, D.; Anderson, P. C.; Bailey, M.; Beaulieu, P.; Bolger, G.; Bonneau, P.; Bös, M.; Cameron, D. R.; Cartier, M.; Cordingley, M. G.; Faucher, A.-M.; Goudreau, N.; Kawai, S. H.; Kukolj, G.; Lagacé, L.; LaPlante, S. R.; Narjes, H.; Poupart, M.-A.; Rancourt, J.; Sentjens, R. E.; George, T, S.; Simoneau, B.; Steinmann, G.; Thibeault, D.; Tsantrizos, Y. S.; Weldon, S. M.; Yong, C.-L.; Llinàs-Brunet, M. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus Nature 2003, 186-189 (Pubitemid 37442587)
10. Zeuzem, S.; Sarrazin, C.; Rouzier, R.; Tarral, A.; Brion, N.; Forestier, N.; Gupta, S.; Deckman, D.; Fellows, K.; Hussain, M.; Cutler, D.; Zhang, J. In 56th Annual Meeting of AASLD, San Francisco, CA, 2005.
11. Venkatraman, S.; Bogen, S. L.; Arasappan, A.; Bennett, F.; Chen, K.; Jao, E.; Liu, Y.-T.; Lovey, R.; Hendrata, S.; Huang, Y.; Pan, W.; Parekh, T.; Pinto, P.; Popov, V.; Pike, R.; Ruan, S.; Santhanam, B.; Vibulbhan, B.; Wu, W.; Yang, W.; Kong, J.; Liang, X.; Wong, J.; Liu, R.; Butkiewicz, N.; Chase, R.; Hart, A.; Agrawal, S.; Ingravallo, P.; Pichardo, J.; Kong, R.; Baroudy, B.; Malcolm, B.; Guo, Z.; Prongay, A.; Madison, V.; Broske, L.; Cui, X.; Cheng, K.-C.; Hsieh, T. Y.; Brisson, J.-M.; Prelusky, D.; Korfmacher, W.; White, R.; Bogdanowich-Knipp, S.; Pavlovsky, A.; Bradley, P.; Saksena, A. K.; Ganguly, A.; Piwinski, J.; Girijavallabhan, V.; Njoroge, F. G. Discovery of (1 R,5 S)- N -[3-Amino-1-(cyclobutylmethyl)-2?3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl) -amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0] hexane-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable, hepatitis C virus NS3 protease inhibitor: A potential therapeutic agent for the treatment of hepatitis C infection J. Med. Chem. 2006, 49, 6074-6086
12. Reesink, H. W.; Zeuzem, S.; Weegink, C. J.; Forestier, N.; van Vilet, A.; Van de Wetering de Rooij, J.; McNair, L.; Purdy, S.; Kauffmann, R.; Alam, J.; Jansen, P. L. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: A phase 1b placebo-controlled randomized study Gastroenterology 2006, 131, 997-1002
13. Perni, R. B.; Almquist, S. J.; Byrn, R. A.; Chandorkar, G.; Chaturvedi, P. R.; Courtney, L. F.; Decker, C. J.; Dinehart, K.; Gates, C. A.; Harbeson, S. L.; Heiser, A.; Kalkeri, G.; Kolaczkowski, E.; Lin, K.; Luong, Y.-P.; Rao, B. G.; Taylor, W. P.; Thomson, J. A.; Tung, R. D.; Wei, Y.; Kwong, A. D.; Lin, C. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease Antimicrob. Agents Chemother. 2006, 50, 899-909
14. Seiwert, S. D.; Andrews, S. W.; Jiang, Y.; Serebryany, V.; Tan, H.; Kossen, K.; Rajagopalan, P. T. R.; Misialek, S.; Stevens, S. K.; Stoycheva, A.; Hong, J.; Lim, S. R.; Qin, X.; Rieger, R.; Condroski, K. R.; Zhang, H.; Do, M. G.; Lemieux, C.; Hingorani, G. P.; Hartley, D. P.; Josey, J. A.; Pan, L.; Beigelman, L.; Blatt, L. M. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227) Antimicrob. Agents Chemother. 2008, 52 (12) 4432-4441
15. Raboisson, P.; de Kock, H.; Rosenquist, A.; Nilsson, M.; Salvador-Oden, L.; Lin, T.-I.; Roue, N.; Ivanov, V.; Wahling, H.; Wickstrom, K.; Hamelink, E.; Edlund, M.; Vrang, L.; Vendeville, S.; Van de Vreken, W.; McGowan, D.; Tahri, A.; Hu, L.; Boutton, C.; Lenz, O.; Delouvroy, F.; Pille, G.; Surleraux, D.; Wigerinck, P.; Samuelsson, B.; Simmen, K. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350 Bioorg. Med. Chem. Lett. 2008, 18, 4853-4858
16. Liverton, N. J.; Carroll, S. S.; DiMuzio, J.; Fandozzi, C.; Graham, D. J.; Hazuda, D.; Holloway, M. K.; Ludmerer, S. W.; McCauley, J. A.; McIntyre, C. J.; Olsen, D. B.; Rudd, M. T.; Stahlhut, M.; Vacca, J. P. MK-7009: A potent and selective inhibitor of hepatitis C virus NS3/4A protease Antimicrob. Agents Chemother. 2010, 54 (1) 305-311
17. Zhang, R.; Beyer, B. M.; Durkin, J. Ingram, R.; Njoroge, F. G.; Windsor, W. T.; Malcolm, B. A. A continuous spectrophotometric assay for the hepatitis C virus serine protease Anal. Biochem. 1999, 270, 268-275
18. Lohmann, V.; Körner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line Science 1999, 285, 110-113
19. Arasappan, A.; Padilla, A. I.; Jao, E.; Bennett, F.; Bogen, S. L.; Chen, K. X.; Pike, R. E.; Sannigrahi, M.; Soares, J.; Venkatraman, S.; Vibulbhan, B.; Saksena, A. K.; Girijavallabhan, V.; Tong, X.; Cheng, K.-C.; Njoroge, F. G. Toward second generation hepatitis C virus NS3 serine protease inhibitors: Discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile J. Med. Chem. 2009, 52, 2806-2817
20. Bogen, S. L.; Pan, W.; Ruan, S.; Nair, L. G.; Arasappan, A.; Bennett, F.; Chen, K. X.; Jao, E.; Venkatraman, S.; Vibulbhan, B.; Liu, R.; Cheng, K.-C.; Guo, Z.; Tong, X.; Saksena, A. K.; Girijavallabhan, V.; Njoroge, F. G. Toward the back-up of boceprevir (SCH 503034): Discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles J. Med. Chem. 2009, 52, 3679-3688
21. Venkatraman, S.; Blackman, M.; Wu, W.; Nair, L.; Arasappan, A.; Padilla, A.; Bogen, S.; Bennett, F.; Chen, K.; Pichardo, J.; Tong, X.; Prongay, A.; Cheng, K.-C.; Girijavallabhan, V.; Njoroge, F. G. Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies Bioorg. Med. Chem. 2009, 17, 4486-4495
22. Tong, X.; Arasappan, A.; Bennett, F.; Chase, R.; Feld, B.; Guo, Z.; Hart, A.; Madison, V.; Malcolm, B.; Pichardo, J.; Prongay, A.; Ralston, R.; Skelton, R.; Xia, E.; Njoroge, F. G. Preclinical characterization of SCH 900518, a novel mechanism-based inhibitor of HCV NS3 protease J. Hepatol. 2009, 50 (Suppl 1) S351
23. Reesink, H. W.; Bergmann, J. F.; de Bruijne, J.; Weegink, C. J.; van Lier, J.; van Vliet, A.; Keung, A.; Li, J.; O'Mara, E.; Treitel, M. A.; Hughes, E. A.; Janssen, H. L. A.; de Knegt, R. J. Safety and antiviral activity of SCH 900518 administered as monotherapy and in combination with peginterferon alfa-2b to naive and treatment-experienced HCV-1 infected patients J. Hepatol. 2009, 50 (Suppl 1) S35-S36